| 創建日期 | 上櫃日期 | 董事長 | 總經理 |
|---|---|---|---|
| 89/11/13 | 105/09/26 | 林榮錦 | 林榮錦 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| -0.92(Q2) | 0 | 6.02 | 0% |
| 實收資本額 | 已發行普通股 | ||
| 1,630,938,250 | 163,093,825 | ||
| 主要經營業務 | |||
| 新藥開發 | |||
| 公司網址 | |||
| lumosa.com.tw | |||
順藥(6535) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 7,488 | 2,290 | -10.6% | 227% | 38,045 | 12,143 | 213.3% |
| 2023/07 | 8,376 | 2,147 | 773.4% | 290.1% | 30,557 | 9,852 | 210.2% |
| 2023/06 | 959 | 2,364 | -90.7% | -59.4% | 22,182 | 7,705 | 187.9% |
| 2023/05 | 10,353 | 60 | 257.9% | 17155% | 21,223 | 5,341 | 297.4% |
| 2023/04 | 2,893 | 2,483 | 697% | 16.5% | 10,869 | 5,281 | 105.8% |
| 2023/03 | 363 | 140 | -88.1% | 159.3% | 7,976 | 2,798 | 185.1% |
| 2023/02 | 3,043 | 2,507 | -33.4% | 21.4% | 7,612 | 2,658 | 186.4% |
| 2023/01 | 4,569 | 151 | -49.3% | 2925.8% | 4,569 | 151 | 2925.8% |
| 2022/12 | 9,019 | 9,665 | 6035.4% | -6.7% | 27,103 | 17,932 | 51.1% |
| 2022/11 | 147 | 429 | -97.4% | -65.7% | 18,084 | 8,267 | 118.7% |
| 2022/10 | 5,646 | 541 | 3740.8% | 943.6% | 17,937 | 7,838 | 128.8% |
| 2022/09 | 147 | 21 | -93.6% | 600% | 12,291 | 7,297 | 68.4% |
| 2022/08 | 2,290 | 591 | 6.7% | 287.5% | 12,143 | 7,276 | 66.9% |
| 2022/07 | 2,147 | 21 | -9.2% | 10123.8% | 9,852 | 6,685 | 47.4% |
| 2022/06 | 2,364 | 2,164 | 3840% | 9.2% | 7,705 | 6,664 | 15.6% |
| 2022/05 | 60 | 21 | -97.6% | 185.7% | 5,341 | 4,500 | 18.7% |
| 2022/04 | 2,483 | 2,164 | 1673.6% | 14.7% | 5,281 | 4,479 | 17.9% |
| 2022/03 | 140 | 69 | -94.4% | 102.9% | 2,798 | 2,315 | 20.9% |
| 2022/02 | 2,507 | 2,236 | 1560.3% | 12.1% | 2,658 | 2,246 | 18.3% |
| 2022/01 | 151 | 10 | -98.4% | 1410% | 151 | 10 | 1410% |
| 2021/12 | 9,665 | 13,523 | 2152.9% | -28.5% | 17,932 | 21,651 | -17.2% |
| 2021/11 | 429 | 11 | -20.7% | 3800% | 8,267 | 8,128 | 1.7% |
| 2021/10 | 541 | 11 | 2476.2% | 4818.2% | 7,838 | 8,117 | -3.4% |
| 2021/09 | 21 | 10 | -96.4% | 110% | 7,297 | 8,106 | -10% |
| 2021/08 | 591 | 1,379 | 2714.3% | -57.1% | 7,276 | 8,096 | -10.1% |
| 2021/07 | 21 | 10 | -99% | 110% | 6,685 | 6,717 | -0.5% |
| 2021/06 | 2,164 | 2,175 | 10204.8% | -0.5% | 6,664 | 6,707 | -0.6% |
| 2021/05 | 21 | 31 | -99% | -32.3% | 4,500 | 4,532 | -0.7% |
| 2021/04 | 2,164 | 2,212 | 3036.2% | -2.2% | 4,479 | 4,501 | -0.5% |
| 2021/03 | 69 | 69 | -96.9% | 0% | 2,315 | 2,289 | 1.1% |
| 2021/02 | 2,236 | 2,150 | 22260% | 4% | 2,246 | 2,220 | 1.2% |
| 2021/01 | 10 | 70 | -99.9% | -85.7% | 10 | 70 | -85.7% |
| 2020/12 | 13,523 | 147,395 | 122836.4% | -90.8% | 21,651 | 172,044 | -87.4% |
| 2020/11 | 11 | 10,768 | 0% | -99.9% | 8,128 | 24,649 | -67% |
| 2020/10 | 11 | 2,211 | 10% | -99.5% | 8,117 | 13,881 | -41.5% |
| 2020/09 | 10 | 49 | -99.3% | -79.6% | 8,106 | 11,670 | -30.5% |
評論0